Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

NCT00312052 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

720

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: E5555
DRUG: Placebo

Sponsor

Eisai Inc.